Lenalidomide maintenance post-ASCT (CALGB 100104 / IFM 2005-02 schedule)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LENALIDOMIDE`

ID	`REG-LENALIDOMIDE-MAINTENANCE`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MM-2023` `SRC-NCCN-MM-2025`

Notes

CALGB 100104 (McCarthy 2012; updated 2017): post-ASCT lenalidomide maintenance vs placebo improved mPFS (46 vs 27 mo) AND mOS (113 vs 84 mo, HR 0.72). IFM 2005-02 confirmed PFS benefit. NCCN Cat 1 for all-comers post-ASCT. Counsel patient on second primary malignancy risk (~5-7% absolute increase, mostly skin + AML/MDS) BEFORE consent. Stop indefinitely on progression; ixazomib OR bortezomib maintenance alternatives for high-risk cytogenetics (separate Regimen entities).

Used By

Indication

IND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCE - IND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCE

Regimen

REG-DARA-LEN-MAINTENANCE - Daratumumab + Lenalidomide maintenance post-ASCT (PERSEUS schedule)